Form 4: ResMed CEO Michael Farrell Executes Stock Options and Sells Shares Under 10b5-1 Plan
SEC Form 4 Filing
ResMed's CEO, Michael J. Farrell, exercised stock options and sold a portion of the acquired shares under a pre-arranged Rule 10b5-1 trading plan.
Summary
- On May 7, 2025, Michael J. Farrell, the CEO of ResMed Inc., exercised options to acquire 8,009 shares of ResMed common stock at a price of $101.64 per share.
- Simultaneously, Farrell sold 8,009 shares of ResMed common stock at a weighted average price of $243.2268, with individual sales prices ranging from $241.50 to $245.09.
- These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on October 31, 2024.
- Following these transactions, Farrell directly owns 455,503 shares of ResMed common stock and indirectly owns 2,090 shares through the Lisette and Michael Farrell Family Trust.
- He also holds 48,056 ResMed Common Stock Options.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing detailing stock transactions by the CEO. It doesn't inherently convey positive or negative sentiment, but rather provides factual information.
Industry Context
Executive stock transactions are a common occurrence in publicly traded companies. The use of Rule 10b5-1 plans allows insiders to sell shares over a predetermined period, mitigating concerns about trading on non-public information.
Comparison to Industry Standards
- Executive compensation packages in the medical device industry often include stock options as a significant component.
- Companies like Medtronic and Stryker also utilize stock options and similar equity-based compensation plans for their executives.
- The vesting schedules and exercise prices of these options are typically benchmarked against industry standards to attract and retain top talent.
Stakeholder Impact
- The stock sale may have a minor impact on shareholders, depending on market perception of the transaction.
- The transaction does not directly impact employees, customers, suppliers, or creditors.
Key Dates
| Date | Description |
|---|---|
| 11/11/2019 | Date options first become exercisable. |
| 10/31/2024 | Date the Rule 10b5-1 plan was adopted. |
| 04/30/2025 | Date of ResMed stock purchase through the Employee Stock Purchase Plan. |
| 05/07/2025 | Date of stock option exercise and share sale. |
| 05/08/2025 | Date of signature on the SEC Form 4. |
| 11/14/2025 | Expiration date of the ResMed Common Stock Options. |
Keywords
ResMed, Michael Farrell, Stock Options, Rule 10b5-1, SEC Form 4, Insider Trading, Executive Compensation, Share Sale
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.